Joan Mannick - Targeting Disease by Inhibiting mTOR

In the 4th TimePie Longevity Forum, Dr. Joan Mannick shared with us the use of mTOR inhibitors to treat ageing-related conditions. Dr. Joan Mannick is the Chief Executive Officer and Co-Founder of Tornado Therapeutics, which is developing next generation mTOR inhibitors to treat ageing-related diseases. Prior to joining Tornado, she was Head of Research and Development at Life Biosciences and Chief Medical Officer of resTORbio. Dr. Mannick was a faculty member at Harvard Medical School and University of Massachusetts Medical School. Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine and an Infectious Disease fellowship at Harvard Medical School. 01:07 Tornado Therapeutics Executive Summary 02:16 mTOR is the key protein that links the availability of nutrients to growth and reproduction 03:03 mTOR activity may become dysregulated with age 04:21 Rapamycin: A very potent and specific inhibitor of mTOR 05:50 Rapamycin extends lifespan in mice even when started late in life and given intermittently 09:04 An ideal rapalog to enhance safety and/or efficacy for ageing-related conditions 10:47 Tornado compounds have distinctive TORC1/TORC2 selectivity 15:08 Tornado's next generation rapalogs’ therapeutic benefit 18:37 Clinical Development Plan for Low Dose TOR-101:Viral Respiratory Tract Infections 23:33 Results of both Phase 2b and 3 26:00 Tornado Pipeline 26:35 Conclusion 26:54 Q&A